Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories' stock experienced a 2.23% decrease on May 8, 2026, closing at $177.62, but rose by 27.98% over the last 12 months. On May 7, 2026, the company reported first-quarter results that exceeded analyst expectations, with adjusted earnings per share of $2.06 and revenue of $995.8 million, leading to a 2.1% rise in shares. In January 2026, Charles River announced two planned acquisitions: K.F. (Cambodia) Ltd. and the remaining equity stake in PathoQuest SAS. The company expects the top end of its organic revenue growth guidance to be at least flat for both consolidated and DSA segments in 2026.

While specific demand seasonality is not explicitly detailed, financial reports indicate some seasonal factors impacting cash flow, such as the payment of annual cash bonuses in the first quarter. The company has observed improving demand trends in its Discovery and Safety Assessment (DSA) segment throughout the second half of 2025, with expectations for stabilizing organic growth in 2026. Smaller biotech firms face pressure due to their dependence on venture capital funding and capital markets.

Charles River Laboratories provides preclinical and clinical laboratory services for drug, vaccine, and medical device development. Its business is segmented into Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions, offering research models, safety assessment, and manufacturing support. The company is known for toxicology studies, animal research models, and microbial testing services, which are vital for regulatory submissions. The Manufacturing Solutions segment includes microbial solutions, biologics testing services, and avian vaccine services.

Charles River Laboratories has a global presence, operating in approximately 120 locations across at least 20 countries, including North America, Europe, and Asia. Specific locations include sites across the United States, the United Kingdom, Germany, France, and Ireland. In 2018, it expanded its biologics infrastructure in Pennsylvania and Germany, and in 2026, it announced a new preclinical facility in Shanghai, China.

Charles River Laboratories has faced scrutiny regarding its use of laboratory animals but emphasizes its commitment to ESG strategies, including renewable electricity and the UN Global Compact. The company is dedicated to developing alternatives to animal testing and highlights its contribution to drug development, noting that it worked on 80% of FDA-approved drugs over the past five years.

Charles River Laboratories' ownership is characterized by a high concentration of institutional investors, a broad free float, and modest insider holdings. As of March 2025, institutional ownership was approximately 106.54%, with mutual funds holding around 75.89%. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and Wellington Management Group Llp. Insiders, including CEO James C. Foster, also hold shares.